We are live on ! Find out more
KCM

Kynam Capital Management Portfolio holdings

AUM $1.62B
1-Year Est. Return 138.67%
This Fund
S&P 500
This Quarter Est. Return
+40.93%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.34B
AUM Growth
+$414M
Cap. Flow
+$90.9M
Cap. Flow %
6.77%
Top 10 Hldgs %
72.61%
Holding
36
New
5
Increased
7
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
MBX
MBX Biosciences
MBX
+$26.7M
2
UTHR icon
United Therapeutics
UTHR
+$22.7M
3
APLS
Apellis Pharmaceuticals
APLS
+$18.9M
4
PHVS icon
Pharvaris
PHVS
+$15M
5
VERA icon
Vera Therapeutics
VERA
+$13.9M

Top Sells

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$13.2M
2
TVTX icon
Travere Therapeutics
TVTX
+$11.1M
3
COGT icon
Cogent Biosciences
COGT
+$7.18M
4
URGN icon
UroGen Pharma
URGN
+$6.72M
5
LQDA icon
Liquidia Corp
LQDA
+$2.49M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
1
Celldex Therapeutics
CLDX
$2.77B
$158M 11.75%
6,100,729
– –
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$1.84B
$131M 9.76%
8,520,000
– –
VERA icon
3
Vera Therapeutics
VERA
$2.54B
$117M 8.71%
4,027,800
+600,913
+18% +$13.9M
COGT icon
4
Cogent Biosciences
COGT
$6.79B
$113M 8.43%
7,886,172
-606,385
-7% -$7.18M
PCVX icon
5
Vaxcyte
PCVX
$7.89B
$111M 8.24%
3,071,588
– –
VRDN icon
6
Viridian Therapeutics
VRDN
$2.13B
$95.6M 7.11%
4,427,927
– –
CGON icon
7
CG Oncology
CGON
$6.11B
$80.8M 6.01%
2,005,205
-452,462
-18% -$13.2M
BCRX icon
8
BioCryst Pharmaceuticals
BCRX
$2.37B
$71.3M 5.31%
9,390,270
+926,528
+11% +$7.72M
BEAM icon
9
Beam Therapeutics
BEAM
$2.58B
$61.1M 4.55%
2,517,647
+100,000
+4% +$1.99M
IMCR icon
10
Immunocore
IMCR
$1.78B
$36.7M 2.73%
1,009,267
+33,000
+3% +$1.12M
MBX
11
MBX Biosciences
MBX
$2.95B
$35M 2.61%
+2,000,000
New +$26.7M
ENGN icon
12
enGene Therapeutics
ENGN
$122M
$34.1M 2.54%
4,994,090
– –
WVE icon
13
Wave Life Sciences
WVE
$1.12B
$33.4M 2.49%
4,560,053
– –
TYRA icon
14
Tyra Biosciences
TYRA
$1.82B
$32.6M 2.43%
2,329,998
– –
TVTX icon
15
Travere Therapeutics
TVTX
$5.33B
$22.7M 1.69%
949,727
-590,964
-38% -$11.1M
DVAX
16
DELISTED
Dynavax Technologies
DVAX
$21.3M 1.59%
2,145,319
– –
NRIX icon
17
Nurix Therapeutics
NRIX
$2.43B
$20M 1.49%
2,168,605
+995,000
+85% +$10.3M
UTHR icon
18
United Therapeutics
UTHR
$26.3B
$20M 1.49%
+67,588
New +$22.7M
APLS
19
DELISTED
Apellis Pharmaceuticals
APLS
$18.3M 1.36%
+808,607
New +$18.9M
PHVS icon
20
Pharvaris
PHVS
$2.39B
$16.8M 1.25%
+675,000
New +$15M
RLAY icon
21
Relay Therapeutics
RLAY
$4.02B
$15.1M 1.12%
2,887,014
– –
CGEM icon
22
Cullinan Oncology
CGEM
$1.05B
$13.7M 1.02%
2,302,172
+206,174
+10% +$1.51M
CTMX icon
23
CytomX Therapeutics
CTMX
$705M
$11.6M 0.87%
3,646,503
+1,492,090
+69% +$3.36M
AMRN
24
Amarin Corp
AMRN
$284M
$9.44M 0.7%
576,111
– –
BNR
25
Burning Rock Biotech
BNR
$94.4M
$8.61M 0.64%
994,883
– –
1
2

Similar funds

IPW
Invictus Private Wealth Denver, Colorado $1.62B AUM 22.63% 1-Year Est. Return
WIC
Woodmont Investment Counsel Nashville, Tennessee $1.62B AUM 18.92% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
TLFA
True Link Financial Advisors San Francisco, California $1.62B AUM 8.33% 1-Year Est. Return
KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
PRA
Pine Ridge Advisers New York $1.62B AUM 16.97% 1-Year Est. Return
BW
Browning West Los Angeles, California $1.62B AUM 22.28% 1-Year Est. Return
CC
Covalis Capital London, United Kingdom $1.63B AUM 27.84% 1-Year Est. Return

Kynam Capital Management's Q3 2025 Portfolio in Review

As of Q3 2025, Kynam Capital Management held 36 positions worth $1.34B, up 45% from $929M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Kynam Capital Management deployed $90.9M of net new capital in Q3 2025, opening 5 new positions and adding to 7 existing holdings. Its largest new stake was MBX Biosciences: 2,000,000 shares worth $35M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was CG Oncology, an estimated $13.2M trimmed.

  • Kynam Capital Management's largest Q3 2025 buy was MBX Biosciences: 2,000,000 shares worth $35M.
  • Kynam Capital Management added most to Vera Therapeutics in Q3 2025, an estimated $13.9M increase.
  • Kynam Capital Management's biggest Q3 2025 reduction was CG Oncology, cutting an estimated $13.2M.
  • Kynam Capital Management fully exited Liquidia Corp in Q3 2025, selling an estimated $2.49M.
  • Kynam Capital Management's ten largest holdings make up 73% of its $1.34B portfolio in Q3 2025.
  • Kynam Capital Management opened 5 new positions and closed 1 in Q3 2025.
  • Kynam Capital Management's portfolio value rose 45% quarter-over-quarter to $1.34B.

Based on Kynam Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.